IL33 and atopic eczema: Another anti-IL-33 monoclonal antibody, Etokimab (AnaptysBio), is also under evaluation or completed Phase2a trials for moderate-to-severe adult atopic dermatitis, chronic rhinosinusitis with nasal polyps, asthma and peanut allergy (13).